EUVIMEDEUVIMED entdecken
Crossref

Lecanemab (Leqembi) for Alzheimer's Disease

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AduhelmAlzheimer's diseaseLeqembiaducanumabadverse effectsdosageefficacylecanemabsafety

Substanzen

lecanemabAntibodies, Monoclonal, Humanized

Zitieren

APA

(2023). Lecanemab (Leqembi) for Alzheimer's Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669a

Vancouver

Lecanemab (Leqembi) for Alzheimer's Disease. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669a

BibTeX
@article{euvimed2023,
  title = {Lecanemab (Leqembi) for Alzheimer's Disease},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669a}
}
Kostenlos starten →